NEW YORK (Reuters Health) – Two-thirds of patients with diabetes achieve a good visual outcome of 20/40 or better after cataract surgery, according to one of the largest studies to assess visual acuity in people with diabetes undergoing cataract surgery. The 67% rate of good visual outcomes in treated eyes in the study is comparable
Intravitreal injections with aflibercept (Eylea) don’t improve the visual acuity of people with nonproliferative diabetic retinopathy (NPDR), researchers say. The treatments do reduce the risk for center-involved diabetic macular edema and proliferative diabetic retinopathy, however, said Adam R. Glassman, MS, principal investigator of the DRCR Retina Network Coordinating Center, Tampa, Florida. “Some clinicians may decide
Hydroxychloroquine can be used safely and effectively with attention to dosing, risk factors, and screening, but communication among physicians, patients, and eye care specialists is key to optimizing outcomes and preventing complications, according to a joint statement from four medical societies. The American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and the
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok